The Employment Report for November 2013: Unanticipated Economic Report Impacts Pharma Industry Restructure

Share Article reports: Though fears from the two week government shutdown had analysts projecting bleak jobs figures from the Labor Department; Friday's report showed job creation was still underway with the addition of 204,000 jobs. (, [11/8/2013])

by Loz Pycock

This kind of scaling back builds a solid foundation from which a healthier, longer term employment structure can grow. In this case, this announcement looks like it could end up being good news for US pharmaceuticals.

Thursday the Commerce Department released a Press Statement announcing the GDP grew by 2.8% last quarter. This was the fastest pace since the third quarter in 2012 and far exceeded the modest projections of analysts. This continued the trend in better-than-expected news last week for the nation's economy. (,[11/7/2013])

While the unemployment rate edged up to 7.3% from 7.2% in September, the Department of Labor clarified this was because many federal workers were considered to be unemployed while government offices were closed down. It was also reported that last month's report needed to be rectified to add an additional 60,000 more jobs which were created in September and August more than earlier estimates had suggested. (, [11/8/2013])

"I think everyone was really bracing for a potentially harder impact at the end of last week than we ended up getting, obviously. It was one of those situations where you wanted to hope for the best and prepare for the worst. Realistically, however, where financial matters are concerned, you really can't afford to use the word ‘hope', so you just prepare. The good news is now, of course, since everyone did prepare, the worst did not materialize. Things kept moving forward and now we get to reap the benefits of that preparation," said John Burkhardt, Managing Director of

Novartis has just made a bold strategic move to consolidate its investment holdings by moving out of the UK market, bringing the company 1.7 billion dollars. These tactical restructuring moves will help solidify its pharmaceutical, generic and eye care holdings which are extremely competitive in their respective markets. According to the company's CEO Joe Jimenez, Novartis is open to "any and all options that would allow us to have those businesses achieve their full potential." Novartis shares were up 1.2% after markets were alerted to the news. (, [11/11/13])

"Strategic movement in the right direction and restructuring can mean many positive things for a company as well as its employees. Consolidation of resources can mean a more focused commitment and a clearer corporate direction. This kind of scaling back builds a solid foundation from which a healthier, longer term employment structure can grow. In this case, this announcement looks like it could end up being good news for US pharmaceuticals," says Del Johnston, Manager of Client Relations at is one of the most notable and essential resources for accessing and finding healthcare, pharmaceutical, and bio-tech employment information on the internet. Their employment experts connect real qualified and skilled workers with top industry employers.

A trusted leader in the Healthcare industry, has now been listed as a top resource when learning about the field of nursing and the go to site for jump-starting your career in "95 Great Sites for School Nurses." (


Established in mid-1994, MedZilla is the original and leading web site to serve career and hiring needs for professionals and employers in biotechnology, pharmaceutical sales, medicine, science and healthcare. The MedZilla jobs database contains about 7,500 open positions. The resume database currently contains over 295,000 resumes with 26,500 less than three months old. These resources have been characterized as the largest, most comprehensive databases of their kind on the web in the industries served.

MedZilla(R) is a Registered Trademark owned by MedZilla Inc. Copyright (C)MedZilla, Inc. Permission is granted to reproduce and distribute this text in its entirety, and if electronically, with a link to the URL For permission to quote from or reproduce any portion of this message, please contact MedZilla, Inc. at press(at)medzilla(dot)com

Press Inquiries
Contact: MedZilla, Inc.
Phone: (360) 657-5681

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Del Johnston
MedZilla, Inc.
+1 (360) 657-5681
Email >
Visit website